| pathology | treatment | patient | Demonstrated benefit and harm | k | | | |
|---|
| cardiovascular prevention | anacetrapib | not classified | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| REALIZE, 2015 | anacetrapib vs placebo | | | cardiovascular events ∞ [NaN; ∞] |
| Trial | Treatments | Patients | Method |
|---|
| REALIZE, 2015 | oral anacetrapib 100 mg for 52 weeks (n=204) vs. placebo (n=102) | patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 2·59 mmol/L or higher without cardiovascular disease or 1·81 mmol/L or higher with cardiovascular disease | double-blind Parallel groups Sample size: 204/102 Primary endpoint: percentage change from baseline in LDL-C FU duration: 52 weeks |
|
| cardiovascular prevention | anacetrapib | not classified | versus placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| DEFINE, 2010 | anacetrapib vs placebo | | | all cause death 1.38 [0.56; 3.40] Cardiovascular death 4.00 [0.45; 35.76] Nonfatal stroke 1.00 [0.29; 3.45] Nonfatal myocardial infarction 0.67 [0.24; 1.87] Cardiovascular death, myocardial infarction, stroke 0.76 [0.40; 1.45] cardiovascular events 0.76 [0.40; 1.45] |
| Trial | Treatments | Patients | Method |
|---|
| DEFINE, 2010 | anacetrapib 100mg fr 18 months (n=811) vs. placebo (n=812) | patients with coronary heart disease or at high risk for coronary heart disease | double-blind Parallel groups Sample size: 811/812 Primary endpoint: percent change from baseline in LDL cholesterol at 24 weeks FU duration: |
|
| cardiovascular prevention | bezafibrate | not classified | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| SENDCAP, 1998 | bezafibrate vs placebo | coronary events 0.36 [0.15; 0.87] | | all cause deaths 0.00 [0.00; NaN] cardiac death NaN [NaN; NaN] | | LEADER, 2002 | bezafibrate vs placebo | | | all cause deaths 1.05 [0.89; 1.24] coronary events 0.81 [0.63; 1.05] cardiac death 1.05 [0.84; 1.32] cardiovascular events 0.94 [0.77; 1.15] |
| Trial | Treatments | Patients | Method |
|---|
| SENDCAP, 1998 | bezafibrate 400 mg daily (n=81) vs. placebo (n=83) | type 2 diabetic subjects without a history of clinical cardiovascular | double blind Parallel groups Sample size: 81/83 Primary endpoint: B-mode ultrasound FU duration: 3.0 years | | LEADER, 2002 | bezafibrate 400 mg daily (n=783) vs. placebo (n=785) | men with lower extremity arterial disease | double-blind Parallel groups Sample size: 783/785 Primary endpoint: CHD, stroke FU duration: 4.6y |
|
| cardiovascular prevention | bezafibrate | secondary prevention | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| BECAIT, 1996 | bezafibrate vs placebo | coronary events 0.25 [0.08; 0.84] CV events (including revascularization) 0.26 [0.08; 0.88] | | all cause deaths ∞ [NaN; ∞] coronary deaths ∞ [NaN; ∞] cardiac death NaN [NaN; NaN] non cardiovascular death NaN [NaN; NaN] incident diabetes 0.57 [0.15; 2.26] | | BIP, 2000 | bezafibrate vs placebo | | | Pancreatitis 1.00 [0.32; 3.08] all cause deaths 1.06 [0.86; 1.30] coronary deaths 1.01 [0.71; 1.44] coronary events 0.91 [0.76; 1.08] CV events (including revascularization) 0.93 [0.84; 1.02] MI non fatal 0.87 [0.71; 1.07] stroke (fatal et non fatal) 0.93 [0.68; 1.27] cardiac death 1.01 [0.71; 1.44] Infarctus non mortel et décès coronariens 0.91 [0.76; 1.08] non cardiovascular death 1.03 [0.73; 1.44] |
| Trial | Treatments | Patients | Method |
|---|
| BECAIT, 1996 | bezafibrate 200 mg three times daily (n=47) vs. placebo (n=45)
| dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the event
| double blind Parallel groups Sample size: 47/45 Primary endpoint: change in mean minimum lumen diameter FU duration: 5.0 years
| | BIP, 2000 | bezafibrate 400 mg/d (n=1548) vs. placebo (n=1542) | patients with a previous myocardial infarction or stable angina, total cholesterol of 180 to 250 mg/dL, HDL-C < or =45 mg/dL, triglycerides < or =300 mg/dL, and low-density lipoprotein cholesterol < or =180 mg/dL | double blind Parallel groups Sample size: 1548/1542 Primary endpoint: IDM fatal ou non fatal ou décès coronarien FU duration: 6.2 y |
|
| cardiovascular prevention | clofibrate | not classified | versus placebo or control No demonstrated result for efficacy clofibrate inferior to placebo in terms of all cause deaths in WHO clofibrate, 1978 clofibrate inferior to placebo in terms of non cardiovascular death in WHO clofibrate, 1978 clofibrate inferior to placebo in terms of non cardiovascular death in CDP Clofibrate, 1975 clofibrate inferior to placebo in terms of venous thromboembolism in CDP Clofibrate, 1975 | 8 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| WHO clofibrate, 1978 | clofibrate vs placebo | MI non fatal 0.75 [0.60; 0.94] | all cause deaths 1.27 [1.01; 1.59] non cardiovascular death 1.41 [1.07; 1.85] | Pancreatitis ∞ [NaN; ∞] coronary deaths 1.12 [0.76; 1.65] coronary events 0.83 [0.68; 1.00] décès par cancer 1.35 [0.96; 1.91] cardiac death 1.12 [0.76; 1.65] | | CDP Clofibrate, 1975 | clofibrate vs placebo | coronary deaths 0.85 [0.73; 0.98] cardiac death 0.85 [0.73; 0.98] | non cardiovascular death 1.55 [1.20; 2.01] venous thromboembolism 1.78 [1.08; 2.92] | Pancreatitis 0.00 [0.00; NaN] all cause deaths 0.98 [0.87; 1.11] coronary events 0.93 [0.83; 1.04] décès par cancer 1.05 [0.51; 2.20] MI non fatal 0.94 [0.79; 1.13] | | Scottish, 1971 | clofibrate vs placebo | | | all cause deaths 0.98 [0.66; 1.45] coronary deaths 1.02 [0.65; 1.60] coronary events 0.81 [0.60; 1.11] MI non fatal 0.64 [0.38; 1.07] cardiac death 1.02 [0.65; 1.60] non cardiovascular death 0.84 [0.33; 2.10] | | Newcastle, 1971 | clofibrate vs placebo | all cause deaths 0.63 [0.42; 0.95] coronary deaths 0.59 [0.37; 0.93] coronary events 0.63 [0.48; 0.84] cardiac death 0.59 [0.37; 0.93] | | MI non fatal 0.68 [0.44; 1.03] non cardiovascular death 0.89 [0.30; 2.61] | | Harrold, 1969 | clofibrate vs placebo | | | | | VA Neurology Section, 1974 | clofibrate vs placebo | | | | | Cullen, 1974 | clofibrate vs placebo | | | | | Hanefeld, 1991 | clofibrate vs placebo | | | coronary events 1.04 [0.65; 1.67] |
| Trial | Treatments | Patients | Method |
|---|
| WHO clofibrate, 1978 | clofibrate 1.6 g daily (n=5331) vs. olive oil (n=5296)
| primary prevention, Hommes, de 30 à 59 ans
| double blind Parallel groups Sample size: 5331/5296 Primary endpoint: IDM et/ou mort subite et/ou ischémie FU duration: 5.3 years
| | CDP Clofibrate, 1975 | clofibrate 1.8 mg/d (n=1103) vs. placebo (n=2789) | men, 30-64 y | double blind Parallel groups Sample size: 1103/2789 Primary endpoint: Mortalité totale FU duration: 6.2 years | | Scottish, 1971 | clofibrate 1.6-2 g daily (n=350) vs. placebo (n=367) | Hommes et femmes, de 40 à 69 ans | double blind Parallel groups Sample size: 350/367 Primary endpoint: Mort subite, IDM fatal FU duration: 3.4 years | | Newcastle, 1971 | clofibrate 1.5-2 g daily (n=244) vs. placebo (n=253)
| Hommes et femmes < 65 ans
| double blind Parallel groups Sample size: 244/253 Primary endpoint: Décès coronariens et idm non fatal FU duration: 3.6 y
| | Harrold, 1969 | clofibrate (n=30) vs. placebo (n=33)
| diabetic retinopathy
| double-blind Parallel groups Sample size: 30/33 Primary endpoint: FU duration: 1 years
| | VA Neurology Section, 1974 | clofibrate (n=268) vs. placebo (n=264)
| treatment of cerebrovascular disease
| Parallel groups Sample size: 268/264 Primary endpoint: FU duration: 1.8 years
| | Cullen, 1974 | clofibrate (n=20) vs. placebo (n=20)
|
| Parallel groups Sample size: 20/20 Primary endpoint: FU duration: 2 years
| | Hanefeld, 1991 | clofibric acid 1.6 g/day (n=379) vs. placebo (n=382) | newly diagnosed middle-aged (30- to 55-yr-old) patients with non-insulin-dependent diabetes mellitus | double-blind Parallel groups Sample size: 379/382 Primary endpoint: NA FU duration: 5 years |
|
| cardiovascular prevention | clofibrate | secondary prevention | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Begg, 1971 | clofibrate vs placebo | | | all cause deaths 0.42 [0.14; 1.27] coronary deaths 0.46 [0.15; 1.44] cardiac death NaN [NaN; NaN] | | Acheson, 1972 | clofibrate vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Begg, 1971 | clofibrate (n=76) vs. placebo (n=79)
| peripheral arteriopathy
| Parallel groups Sample size: 76/79 Primary endpoint: FU duration: 3.5 y
| | Acheson, 1972 | clofibrate (n=-9) vs. placebo (n=-9)
| cerebral vascular disease
| NA Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 6 years
|
|
| cardiovascular prevention | etofibrate | diabetic | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Emmerich, 2009 | etofibrate vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Emmerich, 2009 | etofibrate 1g/j (n=-9) vs. placebo (n=-9) | patients with type 2 diabetes mellitus and concomitant diabetic retinopathy | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: not defined FU duration: 12 months |
|
| cardiovascular prevention | fenofibrate | diabetic | versus placebo or control No demonstrated result for efficacy fenofibrate inferior to placebo in terms of Pancreatitis in FIELD, 2005 (diabetic patients) fenofibrate inferior to placebo in terms of venous thromboembolism in FIELD, 2005 (diabetic patients) | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| FIELD, 2005 | fenofibrate vs placebo | MI non fatal 0.76 [0.62; 0.94] cardiovascular events 0.90 [0.81; 0.99] | Pancreatitis 1.74 [1.04; 2.90] venous thromboembolism 1.50 [1.13; 1.99] | all cause deaths 1.10 [0.95; 1.28] coronary deaths 1.18 [0.90; 1.56] coronary events 0.89 [0.76; 1.05] adverse events 1.58 [0.95; 2.64] cardiovascular death 1.10 [0.87; 1.40] décès par cancer 1.14 [0.91; 1.41] Rhabdomyolyses 3.00 [0.31; 28.86] stroke (fatal et non fatal) 0.90 [0.73; 1.12] cardiac death 1.18 [0.90; 1.56] Infarctus non mortel et décès coronariens 0.89 [0.76; 1.05] Myopathies 2.00 [0.18; 22.07] | | DAIS, 2001 | fenofibrate vs placebo | | | all cause deaths 0.68 [0.25; 1.88] coronary events 0.77 [0.53; 1.13] cardiac death 0.61 [0.15; 2.53] non cardiovascular death 0.51 [0.09; 2.75] |
| Trial | Treatments | Patients | Method |
|---|
| FIELD, 2005 | fenofibrate 200mg/d (n=4895) vs. Placebo (n=4900) | participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry | double blind Parallel groups Sample size: 4895/4900 Primary endpoint: coronary events FU duration: 5 years | | DAIS, 2001 | fenofibrate 200 mg/day (n=207) vs. placebo (n=211) | men and women with type 2 diabetes and coronary atherosclerosis | double-blind Parallel groups Sample size: 207/211 Primary endpoint: QCA (minimum lumen diameter) FU duration: 3.3 years |
|
| cardiovascular prevention | fenofibrate | diabetic patients | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ACCORD lipid, 2010 | fenofibrate vs placebo (on top simvastatine) | | | Critère de jugement principal de l'étude 0.93 [0.80; 1.09] Décès toutes causes 0.91 [0.76; 1.10] Evénement coronarien majeur 0.94 [0.81; 1.08] Décès cardiovasculaires 0.86 [0.66; 1.13] AVC 1.06 [0.72; 1.56] Cv events (CV death, MI, stroke) 0.93 [0.80; 1.09] |
| Trial | Treatments | Patients | Method |
|---|
| ACCORD lipid, 2010 | fenofibrate on top simvastatin (n=2765) vs. placebo (on top simvastatine) (n=2753) participants were also randomized to either intensive or standard glycemic control and to either intensive or standard blood-pressure control. Glycemic-control ACCORD study was stopped early, in February 2008, because of higher mortality in the intensive-glycemic-control group. All patients were then transferred to a standard glycemia-control regimen | high-risk patients with type 2 diabetes | double-blind Factorial plan Sample size: 2765/2753 Primary endpoint: fatal cardiovascular events, nonfatal MI, or nonfatal stroke FU duration: 4.7y |
|
| cardiovascular prevention | gemfibrozil | not classified | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| VA-HIT, 1999 | gemfibrozil vs placebo | coronary events 0.80 [0.68; 0.94] MI non fatal 0.80 [0.65; 0.97] cardiovascular events 0.78 [0.68; 0.90] | | Pancreatitis 1.00 [0.06; 16.01] all cause deaths 0.90 [0.76; 1.08] coronary deaths 0.79 [0.61; 1.02] décès par cancer 0.88 [0.60; 1.31] Cancers mortels et non mortels 0.91 [0.72; 1.14] stroke (fatal et non fatal) 0.76 [0.55; 1.07] cardiac death 0.79 [0.61; 1.02] non cardiovascular death 1.10 [0.84; 1.44] | | Helsinki (HHS), 1987 | gemfibrozil vs placebo | coronary events 0.66 [0.48; 0.92] MI non fatal 0.63 [0.44; 0.91] | | Pancreatitis 0.50 [0.12; 1.98] all cause deaths 1.02 [0.67; 1.54] coronary deaths 0.73 [0.37; 1.46] décès par cancer 0.99 [0.43; 2.29] cardiac death 0.73 [0.37; 1.46] non cardiovascular death 1.24 [0.73; 2.12] | | HHS (Frick)(secondary prev subgroup), 1993 | gemfibrozil vs placebo | | | all cause deaths 1.61 [0.80; 3.27] cardiac death 2.17 [0.95; 4.95] non cardiovascular death 0.51 [0.09; 2.76] | | LOCAT, 1997 | gemfibrozil vs placebo | | | coronary events 1.01 [0.36; 2.81] |
| Trial | Treatments | Patients | Method |
|---|
| VA-HIT, 1999 | gemfibrozil 1.2g daily (n=1264) vs. placebo (n=1267) | men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less | double blind Parallel groups Sample size: 1264/1267 Primary endpoint: nonfatal myocardial infarction or death from coronary causes FU duration: 5.1 years | | Helsinki (HHS), 1987 | gemfibrozil 1,2 g/d (n=2046) vs. placebo (n=2035)
| asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5.2 mmol per liter]
| double blind Parallel groups Sample size: 2046/2035 Primary endpoint: CHD events FU duration: 5 years
| | HHS (Frick)(secondary prev subgroup), 1993 | gemfibrozil 600 mg twice daily (n=311) vs. placebo (n=317) | individuals who exhibited symptoms and signs of possible coronary heart disease | double blind Parallel groups Sample size: 311/317 Primary endpoint: cardiac events FU duration: 5.0 years | | LOCAT, 1997 | gemfibrozil 1200 mg/d (n=197) vs. placebo (n=198) | post-coronary bypass men, who had an HDL cholesterol concentration < or = 1.1 mmol/L and LDL cholesterol < or = 4.5 mmol/L | double blind Parallel groups Sample size: 197/198 Primary endpoint: diameters FU duration: 32 months |
|
| cardiovascular prevention | niacin | not classified | versus placebo or control No demonstrated result for efficacy | 7 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CDP niacin, 1975 | niacin vs placebo | coronary events 0.85 [0.76; 0.96] MI non fatal 0.74 [0.60; 0.90] | | all cause deaths 0.96 [0.85; 1.08] coronary deaths 0.95 [0.82; 1.09] décès par cancer 0.93 [0.44; 2.00] non cardiovascular death 1.15 [0.77; 1.70] | | VA drugs, 1968 | niacin vs control | | | all cause deaths 1.03 [0.59; 1.82] cardiac death 1.05 [0.56; 1.95] non cardiovascular death 0.93 [0.17; 4.96] | | AIM-HIGH, 2011 | niacin vs placebo (on top statin) | | | major CHD events 1.04 [0.80; 1.34] stroke 1.78 [0.95; 3.33] cardiovascular events 1.02 [0.87; 1.18] | | HPS 2-Thrive | niacin vs placebo (on top statin) | | | coronary death 1.04 [0.88; 1.22] all-cause death 1.09 [0.99; 1.20] major CHD events 0.96 [0.87; 1.07] cardiovascular deaths 1.09 [0.96; 1.24] stroke 1.00 [0.88; 1.13] cardiovascular events 0.96 [0.90; 1.03] | | Oxford Niaspan Study, 2009 | niacin vs placebo (on top statin) | | | | | ARBITER 2, 2009 | niacin vs placebo (on top statin) | | | major CHD events 0.92 [0.13; 6.38] cardiovascular deaths 0.46 [0.04; 4.97] stroke 0.00 [0.00; NaN] cardiovascular events 0.39 [0.11; 1.47] | | HATS, 2001 | niacin vs placebo (on top statin) | | | all-cause death 1.00 [0.06; 15.71] major CHD events 0.20 [0.02; 1.63] cardiovascular deaths 1.00 [0.06; 15.71] stroke 0.00 [0.00; NaN] cardiovascular events 0.40 [0.13; 1.22] |
| Trial | Treatments | Patients | Method |
|---|
| CDP niacin, 1975 | niacin 3 mg/d (n=1119) vs. placebo (n=2789)
| Hommes, de 30 à 64 ans
| double blind Parallel groups Sample size: 1119/2789 Primary endpoint: Mortalité totale FU duration: 6.2 years
| | VA drugs, 1968 | niacin (n=77) vs. (n=143) | | double blind Parallel groups Sample size: 77/143 Primary endpoint: FU duration: 3.2 years | | AIM-HIGH, 2011 | high-dose, extended-release niacin in gradually increasing doses up to 2000 mg daily (+ simvastatin) (n=1718) vs. placebo (n=1691) | patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesterol | double blind Parallel groups Sample size: 1718/1691 Primary endpoint: CHD death, MI, ischaemic stroke, NSTEMI FU duration: 32 months | | HPS 2-Thrive | 2 g of extended-release niacin and 40 mg of laropiprant (n=12838) vs. placebo (n=12835) | patients with vascular disease | double blind Parallel groups Sample size: 12838/12835 Primary endpoint: CHD death, stoke, CABG FU duration: 3.9y (median) | | Oxford Niaspan Study, 2009 | niacin 2g daily (added to statin therapy) (n=35) vs. placebo (statins alone) (n=36) | patients with low HDL-C (<40 mg/dl) and either a type 2 diabetes with coronary heart disease or a carotid/peripheral atherosclerosis | double blind Parallel groups Sample size: 35/36 Primary endpoint: carotid artery wall area FU duration: 1 year | | ARBITER 2, 2009 | long-acting niacin target dose of 1 g/day (added to statin therapy) (n=87) vs. placebo (n=80) | patients with known coronary artery disease and well controlled on statin therapy | double blind Parallel groups Sample size: 87/80 Primary endpoint: carotid intima-media thickness FU duration: 1 y | | HATS, 2001 | simvastatin plus niacin (n=73) vs. placebo (n=73) factorial design with antioxidant vitamins | patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels | double blind Factorial plan Sample size: 73/73 Primary endpoint: cardiovascular event FU duration: 3 y |
|
| cardiovascular prevention | niacin | not classified | versus ezetimibe No demonstrated result for efficacy niacin inferior to ezetimibe in terms of cardiovascular events in ARBITER 6-HALTS (niacin vs ezetimibe), 2009 | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ARBITER 6-HALTS (niacin vs ezetimibe), 2009 | niacin vs ezetimibe | major CHD events 0.21 [0.05; 0.95] | cardiovascular events 29.49 [15.69; 55.42] | |
| Trial | Treatments | Patients | Method |
|---|
| ARBITER 6-HALTS (niacin vs ezetimibe), 2009 | extended-release niacin 1 g/d, titrated to max tolerable dose up to 2 g/d (HDL-focused strategy) (n=97) vs. ezetimibe 10 mg/d (LDL-focused strategy) (n=111) | patients with known coronary or vascular disease or coronary risk equivalents | open Parallel groups Sample size: 97/111 Primary endpoint: carotid intima-media thickness FU duration: 14 months |
|
| cardiovascular prevention | torcetrapib | not classified | versus placebo No demonstrated result for efficacy torcetrapib inferior to placebo in terms of all cause death in ILLUMINATE, 2007 torcetrapib inferior to placebo in terms of Coronary revascularization in ILLUMINATE, 2007 | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| RADIANCE 1, 2007 | torcetrapib vs placebo | | | all cause death 0.00 [0.00; NaN] Cardiovascular death 0.00 [0.00; NaN] Nonfatal stroke 1.01 [0.06; 16.08] Nonfatal myocardial infarction ∞ [NaN; ∞] | | ILLUMINATE, 2007 | torcetrapib vs placebo | | all cause death 1.58 [1.14; 2.18] Coronary revascularization 1.25 [1.10; 1.42] | CHD death 1.21 [0.77; 1.92] coronary events 1.22 [0.98; 1.51] Cardiovascular death 1.40 [0.91; 2.16] Nonfatal myocardial infarction 1.20 [0.94; 1.53] stroke 1.08 [0.70; 1.65] Cardiovascular death, myocardial infarction, stroke 1.16 [0.95; 1.40] | | RADIANCE 2, 2007 | torcetrapib vs placebo | | | | | ILLUSTRATE, 2007 | torcetrapib vs placebo | | | all cause death 1.35 [0.47; 3.86] CHD death 1.01 [0.06; 16.11] Nonfatal myocardial infarction 0.82 [0.40; 1.69] stroke 0.25 [0.05; 1.18] Coronary revascularization 1.21 [0.95; 1.55] |
| Trial | Treatments | Patients | Method |
|---|
| RADIANCE 1, 2007 | atorvastatin combined with 60 mg of torcetrapib (n=450) vs. atorvastatin monotherapy (n=454)
| patients with heterozygous familial hypercholesterolemia
| open Parallel groups Sample size: 450/454 Primary endpoint: carotid intima–media thickness FU duration: 24 months
| | ILLUMINATE, 2007 | torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod) (n=7533) vs. atorvastatin alone (n=7534) | patients at highcardiovascular risk | double blind Parallel groups Sample size: 7533/7534 Primary endpoint: MACE FU duration: 1.52y | | RADIANCE 2, 2007 | torcetrapib 60mg daily (on top of atorvastatin attitrated dose) (n=377) vs. placebo +atorvastatin attitrated dose (n=375) | patients with mixed dyslipidaemia | double blind Parallel groups Sample size: 377/375 Primary endpoint: maximum intima-media thickness of 12 carotid segments FU duration: 24 months | | ILLUSTRATE, 2007 | atorvastatin plus 60 mg of torcetrapib daily (n=591) vs. atorvastatin monotherapy (n=597) | patients with coronary disease | open Parallel groups Sample size: 591/597 Primary endpoint: intravascular ultrasonography FU duration: 24 months |
|
